An inhibitor of Bcl-2 family proteins induces regression of solid tumoursTilman Oltersdorf, Saul H. Rosenberg, Steven W. Elmore et al.|Nature|2005Cited by 3.4k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J. Souers, Steven W. Elmore, Kylie D. Mason et al.|Nature Medicine|2013Cited by 3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorChristin Tse, Steven W. Elmore, Alexander R. Shoemaker et al.|Cancer Research|2008Cited by 2k
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren Lasko, Kenneth D. Bromberg, Clarissa G. Jakob et al.|Nature|2017Cited by 853
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityWyndham H. Wilson, Rod Humerickhouse, Owen A. O’Connor et al.|The Lancet Oncology|2010Cited by 852